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Transcription factor activator protein-1 (AP-1) super-family is known to modulate expression of array of genes during
development of many cancers and considered as an important target for modern therapeutics. But the role of AP-1 during
development of human oral cancers is still poorly understood. Because oral cancer is one of the most common cancers in
India and south-east Asia, we studied the activation and expression pattern of AP-1 family of proteins and mRNA in different
stages of oral carcinogenesis. Gel-shift assay, western blotting, immunohistochemistry and northern blotting have been used
to assess the binding activity and expression pattern of AP-1 family (c-Jun, JunB, JunD, c-Fos, FosB, Fra-1 and Fra-2) proteins
and mRNA transcripts in a total of 100 fresh oral tissue specimens comprising precancer (n 5 40), cancer (n 5 50) and
healthy control (n 5 10). Constitutive activation of AP-1 with concomitant upregulated expression of majority of AP-1 family of
proteins and mRNA was observed in cancer cases. Interestingly, almost all precancerous cases showed JunD homodimers,
whereas c-Fos/JunD was the most prevalent complex found in cancer tissues. The overexpression of EGFR mRNA, p50:p50/NF-
jB homodimer formation, together with overexpression of pERK and c-Fos proteins in this study suggests an interesting cross
talk between AP-1 and NF-jB pathways in oral cancers. Thus, this study demonstrates differential expression and activation of
AP-1 super-family proteins in relation to severity of lesion and their crucial role in human oral carcinogenesis.
Oral squamous cell carcinoma (OSCC) is the sixth most
common cancer and accounts for 5% of all malignant
tumors worldwide.1 In India and South East Asia, it is the
most common malignancy accounting to 50% of all malig-
nant tumors. Most of the OSCC is attributed to smoking and
alcohol consumption, whereas a proportion of oral cancers
have been demonstrated to contain anogenital HPV
infections.2,3
The activator protein-1 (AP-1) super-family of transcrip-
tion factor is a dimeric protein complex of structurally and
functionally related members of Jun, Fos, ATF (activating
transcription factors) and MAF (musculoaponeurotic sar-
coma) protein families. The homodimerization of Jun pro-
teins (c-Jun, JunB and JunD) or hetrodimerization of Jun
and Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) generates a
transcriptionally active complex interacting through basic
‘‘leucine zipper’’ motif. AP-1 dimers regulate downstream tar-
get gene through interaction with DNA backbone of selective
8 base pair conserved sequence 50TGAGCTCA 30 recognized
as the TPA (12-O-tetradecanoyl phorbol 13-acetate) response
element (TRE) of the regulatory sequences of the wide arrays
of different cellular and viral genes.4,5 In addition to tumor
promoters, the DNA binding of the AP-1 complex to the
TRE sequence is rapidly induced by several growth factors,
cytokines and oncoproteins, implicated in the proliferation,
survival, differentiation and transformation of cells.4,6
Because DNA binding is a necessary prerequisite of transacti-
vation, the expression of different proteins of the Jun and
Fos family is crucial for the activation of downstream genes
regulated by AP-1. AP-1 is also known to control the expres-
sion of several target genes that regulate cell cycle (cyclin D1,
p16), differentiation (myogenin and involucrin), cell survival
(Bcl-2, Bcl-xL and FasL), growth factors (VEGF), cell adhe-
sion (VCAM and ECAM-1) and angiogenesis/invasion
(MMPs, uPA, osteopontin and CD44). As each of the AP-1
family protein is differentially expressed resulting in subtly
different functions and in view of heterogeneity in AP-1
complex composition, it is interesting to investigate the over-
all expression and transactivation pattern of AP-1 proteins in
oral carcinogenesis. Dysregulated activation and aberrant
expression pattern of AP-1 proteins have been observed in
several human cancers including head and neck cancer7,8 and
oral cancer9–11 mainly on cell lines and paraffin sections, but,
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to the best of our knowledge, this study is the first compre-
hensive and detailed analysis defining the role of AP-1 super-
family proteins based on fresh clinical tissue specimens from
oral precancerous and cancer patients.
Therefore, in this study, we have analyzed the expression
pattern and DNA binding activity of Jun and Fos members
of AP-1 family proteins during human oral carcinogenesis
using tissue biopsies of different histopathological grades.
Material and Methods
Tissue specimens
A total 100 fresh oral tissue biopsies were collected compris-
ing 50 malignant, 40 premalignant and 10 normal (control)
oral tissues from the Department of ENT surgery, LNJP hos-
pital, New Delhi, after informed consent from subjects prior
to any chemo/radio therapy. The clinico-epidemiological
characteristics are presented in Table 1. Half portion of biop-
sies collected in cold 1X phosphate buffer saline (PBS) was
immediately processed for molecular biological works, and
the other half was sent for histo-pathological diagnosis in for-
malin solution.
Preparation of protein extract
Protein extracts from biopsies were prepared by the method
of Dignam12 with certain modifications.13 Briefly, the method
involved fine mincing of either fresh tissue or frozen tissue
biopsies stored at 80C, in cold 1X PBS with surgical blade
in petridish on ice. The minced tissue material was later cen-
trifuged at 4,000 rpm at 4C to wash off 1XPBS solution.
The pellet was resuspended in ice-cold buffer A [20 mM
HEPES pH ¼ 7.6, 20% (v/v) glycerol, 10 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 1mM DTT, 1 mM PMSF, 2 mg/ml
leupeptin and 10 mg/ml aprotinin] and incubated on ice for
10 min with frequent vortexing. Lysate was further centri-
fuged at 4,000 rpm for 10 min at 4C to obtain supernatant
as cytoplasmic extract. The remaining pellet containing iso-
lated nuclei was resuspended in buffer B [20 mM HEPES pH
7.6, 25% (v/v) Glycerol, 500 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 1 mM DTT, 1 mM PMSF, 2 mg/ml leupeptin
and 10 mg/ml aprotinin] and centrifuged after incubation for
1 hr with repeated vortexing on ice at 14,000 rpm for 25 min
at 4C to obtain supernatant designated as nuclear extract.
The concentration of protein extracts was determined by
spectrophotometic method, and the extracts were stored in
aliquots at 80C till further use.
Electrophoretic mobility-shift assay
Consensus oligonucleotides of AP-1: 50CGCTTGATGACTCA
GCCGGAA-30, Oct-1: 50-TGTCGAATGCAAATCACTAGAA-
30 and NF-jB: 50AGTTGAGGGGACTTTCCCAGGCC-30 syn-
thesized by Applied Biosystems, and annealed oligonucleotide
were labeled with [c-32P] ATP (3000 Ci/mmol, Jonaki, India)
with T4 polynucleotide kinase. The binding reaction and com-
petition assays were performed to determine the specificity of
DNA probes as described earlier.14 For monitoring composition
of AP-1, NF-jB and Oct-1, following antibodies of Santa Cruz
Biotechnology were used: c-Jun (sc-45), JunB (sc-73), JunD
(sc-74), c-Fos (sc-253), FosB (sc-48), Fra-1 (sc-605), Fra-2
(sc-171), p50 (sc-114), p65 (sc-109), p52 (sc-298), c-Rel (sc-70),
RelB (sc-226) and Bcl-3 (sc-185). The quantitative densitometry
analysis was performed using Alpha Ease FC version 4.1.0
(Alpha Innotech Corporation, IL).
Hybridization probes and Northern blot hybridization
Plasmid harboring cDNAs for c-fos, junD and egfr genes
were kindly provided by Peter Angel (DKFZ, Germany), for
the fra-1 gene by M. Seiki, (Cancer Research Institute, Japan)
and for b-actin by L. Kedes (Medical Center, Palo Alto, CA).
Probes were labeled according to manufacturer’s protocol
(Bangalore Genei, India). Total RNA was extracted by TRI
Reagent as per instruction manual (Sigma, USA). Northern
blotting was carried out by resolving 15 lg of RNA on 1%
agarose-MOPS-formaldehyde gel. Capillary blotted membrane
was washed in 6 SSC, air dried, exposed in phosphorimager
(Fujifilm FLA-5100) after prehybridization and hybridization
in Perfect HYB-PLUS (Sigma) solution as suggested by man-
ufacturer’s protocol.
Quantification of signals of mRNA in Northern blots was
performed by utilizing ImageJ software (Version 1.41, NIH,
USA) for standard densitometric analysis. The intensity of
signals from transcripts was expressed as the mean 6 standard
deviation (SD).
Immunoblotting
Protein extracts (50 lg/lane) were separated in 8–12% poly-
acrylamide gel and electrotransferred on PVDF membranes
(Millipore, Bedford, MA, USA). The membrane was blocked
with 5% milk and incubated overnight in PBS with 5% milk,
0.05% Tween 20 and primary antibody at 4C. These blots
Table 1. Clinico-pathological characteristics of tissue biopsies from
subjects recruited for studies
Characteristics NM PCL OCL
Number of biopsies 10 40 50
Mean age (years) 44.4 6 12.5 46.2 6 6.3 50.6 6 7.6
Male: female ratio 4:1 7:1 6.5:1
Tumour sites
Tongue 4 18 28
Mandibular gingiva 1 5 5
Maxillary gingiva 0 3 4
Buccal mucosa 3 7 7
Palate 0 2 2
Lips 2 5 4
The numbers indicate total cases in each category. Abbreviations: PCL,
precancerous lesions (hyperplastic and dyplastic lesions including
leukoplakia); OCL, oral cancer lesions; NM, normal mucosa.
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were washed, incubated with HRP-anti-rabbit IgG secondary
antibodies and visualized by Luminol detection kit (Santa
Cruz Biotech). Membrane was probed for b-actin expression
as control. The expression level of proteins was quantitated
on an arbitrary scale where strong ¼ þþþþ; medium ¼
þþ; weak ¼ þ and nil/not detectable (Table 2).
Immunohistochemistry
The immunohistochemical staining was performed as follow-
ing: after deparaffinization and rehydration, heat-induced epi-
tope retrieval was done in the 10 mM citrate buffer (pH 6.0).
Nonspecific binding site was blocked using 1.5% blocking se-
rum and after incubating overnight in primary antibody, im-
munoreactivity was visualized according to manufacturer
protocol (ABC staining kit, Santa Cruz Biotech). Intensity
scoring of expression (Table 3) was performed using an arbi-
trary semiquantitative scale: none (); low (þ); moderate
(þþ) and high (þþþþ).
Statistical analysis
The data analysis was performed using the computer software
Graph Pad Instat (version 4.0). Fisher’s exact test (for smaller
numbers on subgroup analysis) was used to compare the
expression of proteins among different histopathological
grades of tissue biopsies. p values (2-tailed) of <0.05 were
considered statistically significant.
Results
The DNA-binding activity of transcription factor AP-1
dimers and the expression profile of its subunits c-Jun, JunB,
JunD, c-Fos, FosB, Fra-1 and Fra-2 were analyzed in all spec-
trums of fresh oral tissues from different sites of oral cavity
as indicated in Table 1. Mean age (6SD) and male: female
gender ratio varied from 44.4 6 12.5 years and 4:1 in control
subjects, 46.2 6 6.3 years and 7:1 in precancer and 50.6 6
7.6 years and 6.5:1 in cancer cases, respectively.
Constitutive activation of AP-1 in oral cancer
The relative DNA binding activity of AP-1 complex was
compared in nuclear extracts from tissue biopsies of normal,
precancerous (PCL) and cancerous lesions (OCL) using
[c-32P] ATP-labeled probe harboring AP-1 consensus
sequence by EMSA. Malignant oral tissues showed a promi-
nent DNA binding activity of AP-1, whereas moderate bind-
ing was also observed in all the precancerous lesions (PCLs).
In contrast, nuclear extract from normal tissues did only
show very weak detectable level of AP-1 activity (Fig. 1a).
Figure 1. Constitutive AP-1 activation in malignant oral biopsies. (a) EMSA of the different grades of oral biopsies with [c-32P] ATP-labeled
AP-1 oligonucleotide. Cancerous lesion (OCL) shows highest AP-1-binding activity. PCL, precancerous lesion. (b) EMSA with labeled Oct-1
probe showing uniform binding in different grades of biopsies. (c) Binding of AP-1 to DNA probe is sequence specific. Binding specificity
was evidenced in nuclear extracts of malignant tissues incubated with unlabelled 100 molar excess of specific competitor (AP-1) probe in
comparison with competition experiment using nonspecific competitor (Oct-1) and then checked for specific AP-1 binding by EMSA. Band
intensities shown were quantified as described in text.
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Thus, the DNA-binding activity of AP-1 showed a gradual
increase with the increasing severity of oral lesions. But no
difference in the binding activity was observed between nor-
mal, PCL and oral cancer lesion (OCL) when Oct-1 was used
as a probe (Fig. 1b), indicating that the modulation of bind-
ing activity was AP-1 specific in oral cancers. The binding
specificity of AP-1 protein complex to its cognate DNA was
also confirmed by competition assay using a 100-fold molar
excess of cold, specific competitor probe of AP-1 and non-
specific competitor, a heterologous probe of transcription fac-
tor Oct-1 as described earlier13 (Fig. 1c).
Alteration in composition of AP-1 complex during oral
cancer progression
To understand the role of elevated binding of AP-1 transcrip-
tion factor in premalignant (Fig. 2a) and malignant lesions
(Figs. 2b and 2c), AP-1 complexes were further dissected to
identify participating AP-1 members using elelectrophoretic
mobility supershift assay. The supershift analysis in majority
of the premalignant cases (n ¼ 37 of 40, 92.5%) has shown
the presence of JunD/JunD homodimers in the AP-1 com-
plex. But to our surprise, no other Jun or Fos members were
observed to be involved in DNA binding in any preneoplastic
lesions. Interestingly, in majority of cancer cases (31 of 50;
62%) a preferential heterodimerization between c-Fos and
JunD (Fig. 2b) instead of canonical dimerization of c-Jun
with c-Fos, was observed. Among some of tumor samples
(n ¼ 19 of 50, 38%), JunB member has also participated in
complex formation as a minor binding partner of c-Fos (Fig.
2c). We observed that in all malignant tissues analyzed show-
ing c-Fos/JunB/JunD complex (Fig. 2c), more than 70% of
supershifted band was formed by c-Fos, while only 50% of
Figure 2. Alteration in composition of DNA binding AP-1 complex during neoplastic progression of oral tissue. (a) Precancerous lesions to
(b and c) cancerous lesions. Supershift analysis using nuclear extracts (10 lg) from PCL (a) and OCL (b, c) with specific antibodies (2 lg
each) either against Jun and Fos members.
Figure 3. Immunoblotting showing differential expression pattern of
AP-1 members in different spectrum of oral lesions. Increased
expression of c-Jun, JunD, JunB, c-Fos and decreased expression of
Fra-1 in oral cancer lesions. Fifty micrograms protein extracts each
from normal, precancerous PCL and OCL cases were resolved on
an 8–10% SDS–PAGE, electrotransferred on PVDF membrane and
probed with antibodies described in text. Equal protein loading,
confirmed by reprobing membrane with b-actin expression.
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the supershifted band of JunD/c-Fos complex was constituted
by c-Fos member only (Fig. 2b) indicating strongly the pri-
mary role of c-Fos protein in generation of AP-1 complex in
oral cancer tissues.
AP-1 family proteins show differential expression pattern
during oral carcinogenesis
Western blotting (Fig. 3 and Table 2) and immunohisto-
chemistry experiments (Fig. 4 and Table 3) were performed
to analyze the level of expression of AP-1 super-family pro-
teins. Western-blotting analysis had shown that among AP-1
members, c-Fos, JunD and JunB proteins were found to be
significantly overexpressed (p < 0.0001) in malignant tissues
when compared with those of controls. A distinct gradual up-
regulated expression was observed, as the lesions progressed
towards malignant changes. Interestingly, a complete opposite
trend was noticed for Fra-1 protein, which showed a very
high expression in all normal oral tissues but gradually
Figure 4. Representative photomicrographs of Immunohistochemical analysis of AP-1 proteins in biopsies. Paraffin embedded (5 lm) oral
tissue sections of normal mucosa, precancerous lesion (PCL) and oral cancerous lesion (OCL) were probed with Jun and Fos antibodies as
described in method section (Original magnification: 200). [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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decreased as the lesions progressed and became nil in cancer
cases (p < 0.0001 in normal vs. cancer; Table 2). Although c-
Jun and Fra-2 were also found to be upregulated in cancer-
ous lesions (p ¼ 0.03, c-Jun; p ¼ 0.02, Fra-2), they were not
elevated remarkably when compared with the high-expression
levels of c-Fos, JunD and JunB in the same samples. To our
surprise, JunD, the only DNA-binding constituent of AP-1
complex of all precancerous cases had not shown any re-
markable overexpression when compared with the cancer
cases while corroborating its overexpression (Fig. 3) with
transactivation pattern (Fig. 2b). An inconsistent pattern of
FosB protein expression was also observed in all spectrums
of oral tissue biopsies from normal, premalignant to malig-
nant lesions.
The expression profile of AP-1 protein members was fur-
ther analyzed in situ by immunohistochemistry in paraffin-
embedded sections and findings were very much in concord-
ance with western blots. Intensity scoring of protein expres-
sion in immunohistochemistry was performed on an arbi-
trary 4-point scale; none (); low (þ); moderate (þþ) and
high (þþþþ) as described in Methods section. Results along
with the statistical analyses are presented in Figure 4 and
Table 3.
Expression of c-Fos protein was nil/low in 100% (10 of
10) of the normal tissue sections examined, 80% precancer-
ous biopsies (16 of 20) showed moderate and 95% tumors
(19 of 20) showed a high expression of c-Fos (p < 0.0001 in
cancer vs. normal and precancer vs. normal). Conversely, for
Fra-1, most of the cancerous oral mucosa (19 of 20) showed
nil to low expression, 30% (6 of 20) of precancerous tissue
showed high positivity, but 70% of normal tissue sections (7
of 10) have showed a high expression (p < 0.0001 in normal
vs. cancer and precancer vs. cancer). About 75–90% of the
malignant sections showed moderate to high immuno-stain-
ing for JunB (18 of 20; p < 0.0001), JunD (16 of 20; p <
0.0004) and c-Jun (15 of 20; p ¼ 0.001) proteins, whereas
their expressions were either nil or low in normal as well as
precancerous mucosa. Low to high immunoreactivity against
Fra-2 antibody was also observed in 85% of cancerous cases
(17 of 20; p ¼ 0.04) each.
Transcriptional profiling of AP-1 members (c-fos, junD and
fra-1) and egfr mRNAs in oral tissue biopsies
The mRNA expression profiles from freshly collected normal,
precancerous and cancerous biopsies for c-fos, junD and fra-1
genes were further determined by northern-blot hybridization.
Densitometric analysis for mRNA transcripts in cancerous
lesions revealed that c-fos, junD and egfr were significantly
overexpressed with mean 6 SD values of 3.0 6 1.20, 2.11 6
0.80 and 1.91 6 0.73, respectively. On the contrary, fra-
1expression was found to be gradually downregulated toward
malignant transformation of oral lesions with mean 6 SD
value of 0.28 6 0.14 (Fig. 5). Interestingly, these members
(c-fos, junD and fra-1) have also shown similar trend of
expression at their protein level as observed by western blot-
ting (Fig. 3) and immunohistochemistry (Fig. 4), suggesting
their regulation at transcriptional level during human oral
carcinogenesis.
c-fos upregulation, activation of NF-jB and induction of
EGFR expression are correlated in oral cancer tissues
Interestingly, we have observed that oral cancer biopsies have
parallel increase in c-fos mRNA (Fig. 5) along with overex-
pressed egfr at both mRNA and protein levels (Figs. 5 and
Fig. 6a).
Because transcription of egfr gene is positively regulated
by NF-jB/p50 homodimers with recruitment of Bcl-3 as a
coactivator,15 we further checked the expression and dimeri-
zation pattern of NF-jB/p50 member in oral cancer cases. As
per our anticipation, upregulation of p50 (Fig. 6a) and Bcl-3
(Fig. 6a) proteins with p50/p50 homodimers (Fig. 6b) was
found in malignant specimens. Moreover, addition of anti-
Bcl-3 antibody resulted in diminished p50/p50 NF-jB DNA-
binding activity in supershift assay in malignant biopsies, as
visualized by densitometry analysis (Fig. 6b, last lane). This
absence of any supershifted band with a diminished DNA
binding indicates an interaction of Bcl-3 antibody with
DNA-binding motif in p50/p50/Bcl-3 ternary complex pres-
ent in oral cancer biopsies. To explore further the molecular
mechanism involved in the induction of c-Fos in OSCC, we
Figure 5. Northern blotting of c-fos, fra-1, junD, egfr and b-actin
mRNA in oral biopsies. Increased expression of c-Fos, junD and
egfr and decreased expression of fra-1 mRNAs during development
of cancer lesions. Reprobing filters with b-actin probes confirmed
equal loading of mRNA.
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checked the expression of a critical upstream regulatory
MAPKinase-pERK1/2, which is affected by EGFR signals.
Western-blot analysis (Fig. 6a) has shown that pERK expres-
sion was highest in malignant oral cases. Taken together,
these data suggest that NF-jB/p50 homodimers activates
EGFR expression, which is correlated with c-Fos induction
via ERK activation in oral cancer tissues.
Discussion
High DNA-binding activity of AP-1 is reported in many epi-
thelial tumors such as cervix, skin, breast and head and
neck.15–17 AP-1 activation is linked with alcohol consump-
tion9 and HPV infections in oral cancers.18 In agreement
with our data, constitutive activation of AP-1 is also reported
in several different head and neck as well as oral cancer cell
lines.7–9
Assuming that altered composition of AP-1 DNA binding
complex regulates its transactivation pattern and conse-
quently expression of downstream targets during carcinogen-
esis,19 we have analyzed the composition of AP-1 complex in
nuclear extracts from tissue biopsies of different grades.
We found a strong DNA-binding activity in oral cancer
tissue contributed by c-Fos/JunD heterodimers in majority of
cancerous tissues, whereas involvement of JunB was also
noticed only in some of malignant cases. Interestingly, almost
all precancerous biopsies have shown only preferential homo-
dimerization of JunD/JunD. A very high expression of c-Fos
protein was confirmed in all malignant oral tissues by west-
ern blotting and immunohistochemistry experiments, which
corroborates the results of supershift assays. Presence of over-
expressed c-Fos was expected in oral cancer lesions as it con-
trols several downstream target genes such as VEGF, MMPs,
collagenase I involved in invasiveness during development of
many cancers including head and neck cancers.10,11,20,21 We
have also seen the presence of JunD with c-Fos in AP-1 com-
plex in majority of oral cancer cases, which again corrobo-
rates our IHC and western-blotting data, suggesting gradually
upregulated JunD protein during carcinogenesis. The rela-
tively lower DNA binding of JunD containing AP-1 complex
in PCL samples but highest in OCL can be explained by the
fact that JunD homodimer binds its cognate DNA sequence
with lower affinity and also posses lower transactivation
potential.22 Similar to our present report, it has been
observed that c-Fos/JunD heterodimer together showed
higher transcriptional activity than JunD homodimers.23
Therefore, we speculate that JunD/JunD homodimer forma-
tion might prevent the precancerous cells entering into can-
cerous condition, but as soon as participation of c-Fos mem-
ber takes place in AP-1 complex formation, the precancerous
cells are pushed further in the aggressive cancerous condi-
tion. Moreover, it is also reported that JunD changes func-
tionally from growth suppressor to growth promoter possibly
by the formation of mutant form of JunD.24 Similar to our
observation of prevalent c-Fos/JunD complex, the same com-
plex also positively regulates the expression of tyrosinase in
melanomas.25 In our supershift studies of cancerous tissues,
involvement of c-Jun and JunB proteins in transcriptionally
active AP-1 complex formation is found to be insignificant
albeit their consistent overexpression were shown by western
blotting and immunohistochemical methods. These results
indicate that overexpressed JunD is the main dimerizing part-
ner of c-Fos in the transactivated AP-1 complex. c-Jun/JunB
complex in malignant cases demonstrated here are either
transcriptionally inactive or have lower DNA binding
capacity as reported by others too.23 Absence of c-Jun in
transcriptionally active AP-1 DNA-binding complex might be
also possible due to the fact that JunB can substitute c-Jun in
vivo.5 In a perfect reverse correlation with upregulated c-fos
and junD expression, the fra-1 mRNA transcripts has
revealed a higher expression in control specimens with a
gradual downregulated trend with increasing severity of
lesion as seen in many cancers.15,26 Our observation is in
sharp contrast to majority of other reports, which showed a
generalized overexpressed Fra-1 in different cancers20; but
overexpressed c-Fos in oral cancer cases found in our study
is in total agreement with other investigators.8,10,11,27
In contrast to other reports based on cell lines7 and tissues
biopsies28 of head and neck cancers, we observed a very dis-
tinct downregulated expression of Fra-1 protein as well as
mRNA in freshly collected malignant oral tissue biopsies.
Although, we understand that a more detailed studies are
needed to elucidate the exact molecular mechanism of fra-1
gene downregulation in oral cancers, some plausible path-
ways involved are interesting here to mention. The inhibited
Figure 6. Upregulated c-Fos expression is correlated with NF-jB/
p50:p50 homodimer mediated EGFR signals in oral cancer cells. (a)
Immunoblotting from the same biopsies shows the elevated
expression level of p50, pERK, EGFR, Bcl-3 and c-Fos proteins. (b)
OCL category of biopsies showed the preferential homodimeration
of p50/p50 in supershift assay. Nuclear extracts from OCL were
incubated with specific antibodies (2 lg each) against each
member for NF-jB proteins. Band intensities were quantified as
described in Material and methods section of text and indicated. C
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positive autoregulation of fra-1 transcription might be operat-
ing in oral cancer cells due to hampered nuclear shuttling of
Fra-1 protein.29,30 Moreover, repressed fra-1 in oral cancer
tissues infected with human Papillomaviruses cannot be ruled
out as seen in 1 of the other major human epithelial cancer
of uterine cervix in females.13,15
Lack of activation domain in Fra-231 can explain the ab-
sence of DNA binding in our gel-shift assays even it is upreg-
ulated in many cancers.32,33 The low-binding activity of JunB
even after its elevated expression can be attributed to its in-
herent lower DNA-binding activity seen in many oral cancer
cell lines.7 We expect that highly prevalent mutated p16 pro-
teins in oral cancer cases might have altered the property of
JunB from antioncogenic to prooncogenic along with its
overexpression in OSCC.
In this study, we have observed overexpressed EGFR in all
malignant cases as shown by others.34–37 Moreover, many
earlier reports38,39 also support our findings of p50/p50 homo-
dimerization with participation of Bcl-3 (Fig. 6b) in NF-jB
complex of oral cancer biopsies. Interestingly, Thornburg
et al.14 have shown overexpressed egfr due to the presence of
co-activator Bcl-3 in p50/NF-jB complex in nasopharyngeal
cancers. These data together indicate that p50 homodimeriza-
tion in NF-jB complex positively regulates egfr expression in
oral cancers.
Additionally, upregulated c-Fos due to activated ERK is a
well-known signaling pathway.40 Similar to our findings of
upregulated pERK1/2 including elevated c-Fos and EGFR
proteins in cancer biopsies (Fig. 6a), ERK1/2, an upstream
kinase of c-Fos, is reported to be activated in oral cancers
through EGFR signals.41,42 In fact, c-Fos is also known as an
established marker of anti-EGFR therapy in many cancer cell
lines including HNSCC.8 Moreover, studies have also docu-
mented the cross-regulation of AP-1 and NF-jB43,44 path-
ways through overexpressed EGFR-mediated activation by
MAPKinase pathways in HNSCC cell lines.8,14 Therefore, in
light of findings of (i) p50/NF-jB activation along with egfr
overexpression and (ii) elevated pERK and c-Fos proteins in
cancer biopsies, we are tempted to speculate that in human
oral cancers NF-jB and AP-1 signals might be coupled as:
p50/p50 (NF-jB) ! EGFR : ! ERK ! c-Fos/AP-1 :.
Additional functional studies and clinical correlation may
provide further insights in signaling connections between
AP-1 and NF-jB that may contributes toward better under-
standing of oral carcinogenesis.
In conclusion, this study demonstrates an important role
of AP-1 as revealed by differential expression and transacti-
vation of AP-1 super-family proteins that occur as a func-
tion of severity of lesions during progression of oral
carcinogenesis.
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